Limitations of the commercially available gene expression test in predicting cutaneous squamous cell carcinoma metastasis and clinical outcomes
Journal of the American Academy of Dermatology · 2025-07 · 93 (1) · 150-154
DOI: 10.1016/j.jaad.2024.05.014 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of the American Academy of Dermatology, 2025-07. Verfasst von Joel L Sax und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Genetics and Genome Sciences, Case Western Reserve University School of Medicine, Cleveland, Ohio. Hauptthemen laut MEDLINE: Skin Neoplasms, Carcinoma, Squamous Cell, Genetic Testing. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 14 Literaturangaben.
Abstract (Originalsprache)
BACKGROUND: Clinical genetic tests are integral to healthcare decision-making. OBJECTIVE: To critically evaluate the DecisionDx cutaneous squamous cell carcinoma test by Castle Biosciences for its dataset biases, gene panel selection, and reported accuracy metrics, providing insight into broader challenges in the clinical genetic testing landscape. METHODS: Independent analyses of the DecisionDx-SCC 40-GEP test data from Castle Biosciences were conducted. These included comparisons to clinical genetic testing standards, analysis of prevalence metrics against national cutaneous squamous cell carcinoma (cSCC) rates, gene ontology of 34 genes for cSCC associations, and evaluation of accuracy metrics. RESULTS: The DecisionDx-SCC dataset showed a metastasis prevalence higher than the national average. Out of 34 genes, 15 had known associations with cSCC. Inconsistencies in the presentation of accuracy metrics were noted, particularly in moderate and high-risk stratifications. CONCLUSION: Analysis of DecisionDx-SCC indicates potential biases and ambiguities. This highlights the need for systematic validation, stressing the necessity for precise and dependable genetic testing in patient care.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Genetics and Genome Sciences, Case Western Reserve University School of Medicine, Cleveland, Ohio.
- Department of Dermatology, Case Western Reserve University School of Medicine, Cleveland, Ohio; Department of Dermatology, University Hospitals, Cleveland, Ohio. Electronic address: Bryan.Carroll@uhhospitals.org.
Zitieren
APA
Sax, J. L., McFarland, C. D., & Carroll, B. T. (2025). Limitations of the commercially available gene expression test in predicting cutaneous squamous cell carcinoma metastasis and clinical outcomes. Journal of the American Academy of Dermatology, 93(1), 150-154. https://doi.org/10.1016/j.jaad.2024.05.014
Vancouver
Sax JL, McFarland CD, Carroll BT. Limitations of the commercially available gene expression test in predicting cutaneous squamous cell carcinoma metastasis and clinical outcomes. Journal of the American Academy of Dermatology. 2025;93(1):150-154. doi:10.1016/j.jaad.2024.05.014
BibTeX
@article{Sax2025,
author = {Sax, Joel L and McFarland, Christopher D and Carroll, Bryan T},
title = {Limitations of the commercially available gene expression test in predicting cutaneous squamous cell carcinoma metastasis and clinical outcomes},
journal = {Journal of the American Academy of Dermatology},
year = {2025},
volume = {93},
number = {1},
pages = {150--154},
doi = {10.1016/j.jaad.2024.05.014}
}
EUVIMED